Arcutis Biotherapeutics, Inc. (ARQT) stock surged +3.59%, trading at $12.69 on NASDAQ, up from the previous close of $12.25. The stock opened at $12.25, fluctuating between $12.12 and $13.39 in the recent session.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Employees | 296 |
Beta | 1.19 |
Sales or Revenue | $59.61M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) stock price is $12.69 in the last trading session. During the trading session, ARQT stock reached the peak price of $13.39 while $12.12 was the lowest point it dropped to. The percentage change in ARQT stock occurred in the recent session was 3.59% while the dollar amount for the price change in ARQT stock was $0.44.
The NASDAQ listed ARQT is part of Biotechnology industry that operates in the broader Healthcare sector. Arcutis Biotherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Kenneth A. Lock
Senior Vice President & Chief Commercial Officer
Dr. David W. Osborne Ph.D.
Chief Technical Officer
Mr. Matthew Richard Moore
Senior Vice President & Chief Bus. Officer
Mr. Scott L. Burrows
Chief Financial Officer, Principal Accounting Officer & Senior Vice President
Mr. Rajvir Madan
Chief Digital & Technology Officer
Ms. Kimberly Lathroum
Vice President of Marketing
Mr. Todd Franklin Watanabe M.A.
Pres, Chief Executive Officer & Director
Dr. Bhaskar Chaudhuri Ph.D.
Co-Founder & Independent Director
Dr. Patrick E. Burnett M.D., Ph.D.
Senior Vice President & Chief Medical Officer
Mr. Eric McIntyre
Head of Investor Relations
Ms. Courtney Barton
Vice President and Chief Compliance Officer & Privacy Officer
Ms. Amanda Sheldon
Head of Corporation Communications
Mr. Masaru Matsuda Esq., J.D.
Senior Vice President, Gen. Counsel & Corporation Sec.
Ms. Patricia A. Turney
Senior Vice President of Operations
ARQT's closing price is 456.58% higher than its 52-week low of $2.28 where as its distance from 52-week high of $13.50 is -6%.
Number of ARQT employees currently stands at 296.
Official Website of ARQT is: https://www.arcutis.com
ARQT could be contacted at phone 805 418 5006 and can also be accessed through its website. ARQT operates from 3027 Townsgate Road, Westlake Village, CA 91361, United States.
ARQT stock volume for the day was 2.55M shares. The average number of ARQT shares traded daily for last 3 months was 2.03M.
The market value of ARQT currently stands at $1.49B with its latest stock price at $12.69 and 117.05M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com